Borstnar, S. et al. 2022. Ribociclib plus letrozole in patients with hormone receptor‐positive, HER2‐negative advanced breast cancer with no prior endocrine therapy: subgroup analysis from the phase 3b CompLEEment‐1 trial: Subgroup analysis of the CompLEEment‐1 trial. Radiology and Oncology. 56, 2 (Jul. 2022), 238–247.